N-Linked glycoengineering for human therapeutic proteins in bacteria
- First Online:
- 544 Downloads
Approx. 70% of human therapeutic proteins are N-linked glycoproteins, and therefore host cells for production must contain the relevant protein modification machinery. The discovery and characterisation of the N-linked glycosylation pathway in the pathogenic bacterium Campylobacter jejuni, and subsequently its functional transfer to Escherichia coli, presents the opportunity of using prokaryotes as cell factories for therapeutic protein production. Not only could bacteria reduce costs and increase yields, but the improved feasibility to genetically control microorganisms means new and improved pharmacokinetics of therapeutics is an exciting possibility. This is a relatively new concept, and progress in bacterial N-glycosylation characterisation is reviewed and metabolic engineering targets revealed.
KeywordsN-Linked glycosylation Therapeutic proteins Campylobacter jejuni E. coli Metabolic engineering
- Chantret I, Dancourt J, Barbat A et al (2005) Two proteins homologous to the N- and C-terminal domains of the bacterial glycosyltransferase Murg are required for the second step of dolichyl-linked oligosaccharide synthesis in Saccharomyces cerevisiae. J Biol Chem 280:9236–9242CrossRefPubMedGoogle Scholar
- Müller D, Bayer K, Mattanovich D (2006) Potentials and limitations of prokaryotic and eukaryotic expression systems for recombinant protein production—a comparative view. In: The 4th recombinant protein production meeting. Microbial Cell Factories, Barcelona, SpainGoogle Scholar
- Varki A, Cummings R, Esko J et al (1999) Essentials of glycobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NYGoogle Scholar